Abbott psoriasis drug passes in trial by WhiteDigitalMedia

VIEWS: 60 PAGES: 2

Abbott Laboratories experimental psoriasis treatment briakinumab succeeds in crucial trial

More Info
									Abbott psoriasis drug passes in trial



Abbott Laboratories experimental psoriasis treatment briakinumab succeeds in crucial trial




Psoriasis treatment drug ‘briakinumab’ from A bbott Laboratories is waiting for U.S. & Europen
regulators to announce their final verdict on it. The company on Monday stated that their drug has
shown superior skin clearance rates compared with a commonly us ed medicine in an important late-
stage clinical trial.

In a 52-week research with 317 patients suffering from moderate to severe psoriasis (a disease of the
immune system), the drug performed better than methotrexate in its ability to clear the hideous, scaly
and often painful skin patches. This symptom is commonly associated with the disease. At 24 weeks,
81.8 percent of briakinumab patients achieved at least a 75 percent skin clearance rate, compared
with 39.9 percent for methotrexate.
According to data presented at the European Association of Dermatology and Venereolog y, 66.2
percent maintained at least a 75 percent clearance rate on the Abbott drug compared with 23.9
percent for methotrexate after 52 weeks.

Briakinumab is a biotechnology drug. It targets proteins which are associated with inflammation called
IL-12/23.

Abbott Laboratories is seeking U.S. and European approval of the drug and will probably receive both
verdicts in the second half of next year. If approved, briakinumab would compete with Johnson &
Johnson's ‘Stelara’, also a new drug which belongs to the same class.

								
To top